Akebia Therapeutics, Inc. splits its revenue into 5 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Auryxia at $20.0 million, 54% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
197
|
37
|
49
|
54
|
58
|
59
|
62
|
57
|
46
|
| Product |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
44
share 95.4%
|
| Auryxia |
—
|
20
-52.8%
share 54.3%
|
25
-46.0%
share 51.8%
|
36
-17.3%
share 67.6%
|
48
+8.5%
share 83.5%
|
42
share 72.3%
|
47
share 75.5%
|
44
share 76.3%
|
44
share 95.4%
|
| Vafseo |
—
|
15
+3.3%
share 40.1%
|
21
+60.4%
share 43.4%
|
16
+31.3%
share 29.5%
|
6
share 10.7%
|
14
share 24.4%
|
13
share 21.3%
|
12
share 21.0%
|
—
|
| License Collaboration And Other Revenue |
—
|
2
+5.0%
share 5.6%
|
2
+17.5%
share 4.8%
|
2
+0.5%
share 2.9%
|
3
+56.6%
share 5.8%
|
2
share 3.4%
|
2
share 3.2%
|
2
share 2.7%
|
2
share 4.6%
|
| License Collaboration And Other Revenue Royalties |
—
|
0
share 0.0%
|
—
|
—
|
—
|
0
share 0.0%
|
0
share 0.0%
|
—
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AKBA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1517022
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.